Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

RECK Gene Polymorphisms Influence NSCLC Susceptibility, but not the Chemotherapy Response Status in Chinese Cohort.

Chen X, Jiang F, Shi N, Zhou H, Zhang L, Chen Y, Zheng Y, Yan TG.

Cell Biochem Biophys. 2014 Jul;69(3):567-71. doi: 10.1007/s12013-014-9832-8.

PMID:
24510537
[PubMed - in process]
2.

The Role of NQO1 Polymorphisms in the Susceptibility and Chemotherapy Response of Chinese NSCLC Patients.

Tian G, Wang M, Xu X.

Cell Biochem Biophys. 2014 Jul;69(3):475-9. doi: 10.1007/s12013-014-9820-z.

PMID:
24464627
[PubMed - in process]
3.

Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.

Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22.

PMID:
23522953
[PubMed - indexed for MEDLINE]
4.

FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.

Fang HM, Tian G, Zhou LJ, Zhou HY, Fang YZ.

Acta Pharmacol Sin. 2013 Apr;34(4):549-54. doi: 10.1038/aps.2012.206. Epub 2013 Mar 25.

PMID:
23524567
[PubMed - indexed for MEDLINE]
5.

Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.

Takenaka K, Ishikawa S, Yanagihara K, Miyahara R, Hasegawa S, Otake Y, Morioka Y, Takahashi C, Noda M, Ito H, Wada H, Tanaka F.

Ann Surg Oncol. 2005 Oct;12(10):817-24. Epub 2005 Aug 8.

PMID:
16132376
[PubMed - indexed for MEDLINE]
6.

Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.

Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS.

Pharmacogenomics. 2011 Jun;12(6):797-808. doi: 10.2217/pgs.11.27. Epub 2011 May 24.

PMID:
21605004
[PubMed - indexed for MEDLINE]
7.

Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.

Pesta M, Kulda V, Topolcan O, Safranek J, Vrzalova J, Cerny R, Holubec L.

Anticancer Res. 2009 Nov;29(11):4535-9.

PMID:
20032402
[PubMed - indexed for MEDLINE]
Free Article
8.

Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan.

Chung TT, Pan MS, Kuo CL, Wong RH, Lin CW, Chen MK, Yang SF.

Carcinogenesis. 2011 Jul;32(7):1063-8. doi: 10.1093/carcin/bgr083. Epub 2011 May 11.

PMID:
21565829
[PubMed - indexed for MEDLINE]
Free Article
9.

Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features.

Chung TT, Yeh CB, Li YC, Su SC, Chien MH, Yang SF, Hsieh YH.

PLoS One. 2012;7(3):e33517. doi: 10.1371/journal.pone.0033517. Epub 2012 Mar 12.

PMID:
22428065
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.

Takemoto N, Tada M, Hida Y, Asano T, Cheng S, Kuramae T, Hamada J, Miyamoto M, Kondo S, Moriuchi T.

Lung Cancer. 2007 Dec;58(3):376-83. Epub 2007 Aug 21.

PMID:
17714826
[PubMed - indexed for MEDLINE]
11.

Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.

Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, Otake Y, Morioka Y, Takahashi C, Noda M, Wada H, Tanaka F.

Eur J Cancer. 2004 Jul;40(10):1617-23.

PMID:
15196549
[PubMed - indexed for MEDLINE]
12.

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D.

PLoS One. 2012;7(3):e33200. doi: 10.1371/journal.pone.0033200. Epub 2012 Mar 29.

PMID:
22479369
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer.

Cui E, Deng A, Wang X, Wang B, Mao W, Feng X, Hua F.

Biochem Cell Biol. 2011 Jun;89(3):308-13. doi: 10.1139/O11-005. Epub 2011 May 27.

PMID:
21619462
[PubMed - indexed for MEDLINE]
14.

Polymorphisms of CHRNA5-CHRNA3-CHRNB4 Gene Cluster and NSCLC Risk in Chinese Population.

Li Z, Bao S, Xu X, Bao Y, Zhang Y.

Transl Oncol. 2012 Dec;5(6):448-52. Epub 2012 Dec 1.

PMID:
23397474
[PubMed]
Free PMC Article
15.

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J.

Oncol Rep. 2012 Apr;27(4):979-86. doi: 10.3892/or.2011.1591. Epub 2011 Dec 13.

PMID:
22179630
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.

Zhao X, Zhang Z, Yuan Y, Yuan X.

Tumour Biol. 2014 May 24. [Epub ahead of print]

PMID:
24859833
[PubMed - as supplied by publisher]
17.

The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients.

Li Y, Geng J, Wang Y, Lu Q, Du Y, Wang W, Li Z.

J Cancer Res Clin Oncol. 2012 Feb;138(2):311-6. doi: 10.1007/s00432-011-1098-6. Epub 2011 Nov 30.

PMID:
22127368
[PubMed - indexed for MEDLINE]
18.

Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.

Li W, Yue W, Zhang L, Zhao X, Ma L, Yang X, Zhang C, Wang Y, Gu M.

Lung. 2012 Feb;190(1):91-8. doi: 10.1007/s00408-011-9338-8. Epub 2011 Nov 23.

PMID:
22109568
[PubMed - indexed for MEDLINE]
19.

Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.

Chen YB, Mu CY, Chen C, Huang JA.

Asia Pac J Clin Oncol. 2014 Jun;10(2):e1-6. doi: 10.1111/ajco.12037. Epub 2012 Nov 21.

PMID:
23167931
[PubMed - in process]
20.

Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer.

Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Mio T, Mishima M.

Oncol Rep. 2011 Feb;25(2):377-82. doi: 10.3892/or.2010.1098. Epub 2010 Dec 10.

PMID:
21165571
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk